Universe · entity
Aisling Capital Management LP
Institutional manager (13F) · CIK 1766721
13F holdings · as of 2026-03-31 · top 13 · reported portfolio $476M
| # | Issuer | Value | Shares |
|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | $378M | 5,089,611 |
| 2 | Syndax Pharmaceuticals, Inc. (SNDX) | $31M | 1,316,806 |
| 3 | Monte Rosa Therapeutics Inc (GLUE) | $26M | 1,555,664 |
| 4 | Bicara Therapeutics Inc. (BCAX) | $11M | 568,919 |
| 5 | BridgeBio Oncology Therapeutics (BBOT) | $9M | 1,018,018 |
| 6 | Compass Pathways Plc (CMPS) | $8M | 1,432,336 |
| 7 | Scholar Rock Holding Corporation (SRRK) | $4M | 77,031 |
| 8 | Biomea Fusion Inc (BMEA) | $3M | 2,048,757 |
| 9 | Eupraxia Pharmaceuticals Inc. (EPRX) | $2M | 325,000 |
| 10 | Urogen Pharma Ltd. (URGN) | $2M | 108,000 |
| 11 | Aclaris Therapeutics Inc (ACRS) | $2M | 434,455 |
| 12 | Marker Therapeutics, Inc. (MRKR) | $423k | 325,370 |
| 13 | OnKure Therapeutics, Inc. (OKUR) | $367k | 88,607 |
Source: sec_edgar_13f · public regulatory · retrieved 2026-06-29. Public SEC data; no contact information.